---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-183563"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:52:39.233907+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Q1 revenue $38.2M; net loss narrows to $26.1M; WVE-007 Phase 2a begins Q2 2026

## Summary
- Revenue $38.2M (up from $9.2M); net loss $26.1M (vs $46.9M).
- Cash $544.6M; runway into Q3 2028, excluding GSK milestones.
- FDA accepted Phase 2a multidose portion of WVE-007 (obesity); trial to start Q2 2026.
- Phase 1 six-month data: total fat -5.3%, visceral fat -14.3% (p<0.05), muscle +2.4%.
- WVE-006 AATD data at ATS May 18 & EASL May 29; accelerated approval feedback mid-2026.

## SEC filing metadata
- accession: 0001193125-26-183563
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/0001193125-26-183563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/d135689d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-183563
- JSON: https://secwatch.observer/filing/0001193125-26-183563.json
- Plain text: https://secwatch.observer/filing/0001193125-26-183563.txt

## Key facts
- Earnings Releases
  Wave Life Sciences Ltd. reported financial results for quarter ended March 31, 2026.
  - Period: quarter ended March 31, 2026
  - Result: reported results
  source text: On April 28, 2026, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/0001193125-26-183563-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.